Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
(PubMed) Johansen JS, Harris AK, Rychly DJ, Ergul A
Nissen notes that SURMOUNT-MMOs use of all-cause mortality instead of cardiovascular death, consistent with this post hoc analysis, signals a shift for cardiovascular outcome trials
The goal is preservation, not growth
You start at 0.25 mg weekly for the first four weeks, then increase to 0.5 mg for weeks 5 through 8, then 1 mg for weeks 9 through 12, then 1.7 mg for weeks 13 through 16, and finally the maintenance dose of 2.4 mg from week 17 onward
Even before it added compounded GLP-1s to its portfolio, the company said in its 2023 fourth-quarter earnings call that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025
Foundayo (orforglipron) presents a flexible oral GLP-1 choice with no dietary restrictions
US$ 22.75
US$ 21.93
US$ 28.31
US$ 26.72
US$ 27.34
